Abby Hardy, Author at BioTuesdays

Developments

iBio supporting AzarGen’s development of plant-made rituximab

iBio (NYSE AMERICAN:IBIO) will manufacture and characterize additional supplies of plant-made rituximab for South Africa’s AzarGen, enabling preclinical studies to compare plant-made rituximab to the original molecule...

March 26, 2020

Developments

Profound Medical’s TULSA-PRO now available at Georgia’s renowned Busch Center

Georgia’s renowned Busch Center is now offering Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO procedure to treat unhealthy prostate tissue. The technology, which was cleared by the FDA in August 2019, provides...

March 26, 2020

Developments

iBio begins immunization studies of COVID-19 vaccine candidates

iBio (NYSE AMERICAN:IBIO) commenced immunization studies for its SARS-CoV-2 virus-like particle (VLP) program, IBIO-200, at Texas A&M University System laboratories. The company used its plant-based FastPharming...

March 26, 2020

Developments

Prevail Therapeutics gets FDA fast track designation for frontotemporal dementia gene therapy

Prevail Therapeutics (NASDAQ:PRVL) received FDA fast track designation for PR006, a gene therapy candidate designed to slow the progression of frontotemporal dementia with a GRN mutation. Frontotemporal dementia is the...

March 24, 2020

Executive Moves

Akcea names Damien Devitt as CEO

Damien Devitt, who has been interim CEO of Akcea Therapeutics (NASDAQ:AKCA) since September 2019, has been promoted to CEO, effective immediately, and will continue to serve as a member of Akcea’s board. “With his...

March 24, 2020

Markets

Mackie Research ups Profound Medical to speculative buy

Mackie Research upgraded Profound Medical (TSX:PRN; NASDAQ:PROF) to “speculative buy” from “hold,” but reduced its price target to $16.20 from $26.10 due to the anticipated impact of the coronavirus. The stock closed at...

March 24, 2020

Markets

Analysts see strong rationale for Hepion CRV431’s use in severe COVID-19 cases

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431, a cyclophilin inhibitor with antifibrotic and antiviral properties, may show some effect in the ongoing COVID-19 pandemic, according to Roth Capital Partners and Brookline...

March 20, 2020

Developments

Dicerna gets FDA orphan drug designation for alpha-1 antitrypsin deficiency drug candidate

Dicerna Pharma (NASDAQ:DRNA) received FDA orphan drug designation for DCR-A1AT for the treatment of alpha-1 antitrypsin deficiency, a genetic disorder that can cause lung and liver disease. The company submitted a...

March 19, 2020

Developments

Soligenix reports positive topline results from Phase 3 cutaneous T-cell lymphoma trial

Soligenix (NASDAQ:SNGX) reported positive topline results for its Phase 3 trial assessing SGX301 for the treatment of cutaneous T-cell lymphoma (CTCL). The study enrolled 169 patients who were randomized to receive...

March 19, 2020

Developments

Abeona treats first patient in Phase 3 VIITAL gene therapy trial

Abeona Therapeutics (NASDAQ:ABEO) treated the first patient in its Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The trial, being conducted at Stanford...

March 19, 2020

Author - Abby Hardy

iBio supporting AzarGen’s development of plant-made rituximab

Profound Medical’s TULSA-PRO now available at Georgia’s renowned Busch Center

iBio begins immunization studies of COVID-19 vaccine candidates

Prevail Therapeutics gets FDA fast track designation for frontotemporal dementia gene therapy

Akcea names Damien Devitt as CEO

Mackie Research ups Profound Medical to speculative buy

Analysts see strong rationale for Hepion CRV431’s use in severe COVID-19 cases

Dicerna gets FDA orphan drug designation for alpha-1 antitrypsin deficiency drug candidate

Soligenix reports positive topline results from Phase 3 cutaneous T-cell lymphoma trial

Abeona treats first patient in Phase 3 VIITAL gene therapy trial

Follow Us

General

More